Sandbox brain abscess: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
== | ==Brain Abscess <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from Sanford Guide to Antimicrobial Therapy (2010); and | ||
J Neurosci Rural Pract. 2013 August; 4(Suppl 1): S67–S81<ref name="pmid3808066">Carpenter D, Jackson T, Hanley MR (1987) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=3808066 Protein kinase Cs. Coping with a growing family.] ''Nature'' 325 (7000):107-8. [http://dx.doi.org/10.1038/325107a0 DOI:10.1038/325107a0] PMID: [http://pubmed.gov/3808066 3808066]</ref></SMALL></SMALL></SMALL></SMALL></SMALL> | |||
<font color="#FF4C4C">'''Click on the following categories to expand treatment regimens.'''</font> | |||
{| | {| | ||
| valign=top | | | valign=top | | ||
Line 10: | Line 15: | ||
<div class="mw-customtoggle-table01" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | <div class="mw-customtoggle-table01" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''Primary | ▸ '''Primary Source''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 16: | Line 21: | ||
<div class="mw-customtoggle-table02" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | <div class="mw-customtoggle-table02" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''Contiguous | ▸ '''Contiguous Source''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 22: | Line 27: | ||
<div class="mw-customtoggle-table03" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | <div class="mw-customtoggle-table03" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''Post- | ▸ '''Post-Traumatic''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 28: | Line 33: | ||
<div class="mw-customtoggle-table04" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | <div class="mw-customtoggle-table04" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ '''Post- | ▸ '''Post-Surgical''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 34: | Line 39: | ||
<div class="mw-customtoggle-table05" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | <div class="mw-customtoggle-table05" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ ''' | ▸ '''Metastatic or Cryptogenic''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 40: | Line 45: | ||
<div class="mw-customtoggle-table06" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | <div class="mw-customtoggle-table06" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ ''' | ▸ '''Haematogenous Abscess''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 155: | Line 160: | ||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center |{{fontcolor|#FFF|Haematogenous Abscess }} | ! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center |{{fontcolor|#FFF|Haematogenous Abscess}}<sup>¶</sup> | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen<sup> | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen<sup>#</sup>''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[ | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim]]: 3.75-7.5 mg/kg IV/ po q6-12h | ||
|- | |- | ||
Line 167: | Line 172: | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[ | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Sulfamethoxazole]]: 18.75-37.5 mg/kg/day IV/po q6-12h | ||
|- | |- | ||
Line 177: | Line 182: | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[ | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim]]: 3.75-7.5 mg/kg IV/ po q6-12h | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[ | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Sulfamethoxazole]]: 18.75-37.5 mg/kg/day IV/po q6-12h | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | ||
Line 229: | Line 234: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[ | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-Sulfamethoxazole ]] 5/25 mg/kg po or IV q12h for 30 days ''''' | ||
|- | |- | ||
|} | |} | ||
|} | |} | ||
|} | |} | ||
<small><small><small><small><sup>†</sup>:If Pseudomonas aeruginosa is suspected.</small></small></small><small> | |||
<small><small><small><small><sup>‡</sup>:The aim is to keep the serum levels at 15-25mg/L</small></small></small><small> | |||
<small><small><small><small><sup>¶</sup>:After 3-6 wks of IV therapy, switch to po therapy. Immunocompetent pts: TMP-SMX, minocycline or AM-CL x 3+months. Immunocompromised pts: Treat with 2 drugs for at least one year.</small></small></small><small> | |||
<small><small><small><small><sup>#</sup>: If multiorgan involvement some add amikacin 7.5 mg/kg q12h. |
Revision as of 20:34, 27 January 2014
==Brain Abscess Adapted from Sanford Guide to Antimicrobial Therapy (2010); and
J Neurosci Rural Pract. 2013 August; 4(Suppl 1): S67–S81[1]
Click on the following categories to expand treatment regimens.
Brain Abscess ▸ Primary Source ▸ Contiguous Source ▸ Post-Traumatic ▸ Post-Surgical ▸ Metastatic or Cryptogenic ▸ Haematogenous Abscess ▸ Immunocompromised |
|
†:If Pseudomonas aeruginosa is suspected.
‡:The aim is to keep the serum levels at 15-25mg/L
¶:After 3-6 wks of IV therapy, switch to po therapy. Immunocompetent pts: TMP-SMX, minocycline or AM-CL x 3+months. Immunocompromised pts: Treat with 2 drugs for at least one year.
#: If multiorgan involvement some add amikacin 7.5 mg/kg q12h.
- ↑ Carpenter D, Jackson T, Hanley MR (1987) Protein kinase Cs. Coping with a growing family. Nature 325 (7000):107-8. DOI:10.1038/325107a0 PMID: 3808066